Toward Value-Based Reimbursement for Hemophilia A in the UAE: A Multi-Stakeholder Perspective.
8 affiliations
- 1Emirates Health Economics Society, Dubai P.O. Box 6600, United Arab Emirates.
- 2International Society for Pharmacoeconomics and Outcomes Research, UAE Chapter, Abu Dhabi P.O. Box 44171, United Arab Emirates.
- 3Mediclinic, Dubai P.O. Box 505004, United Arab Emirates.
- 4MetLife, Dubai P.O. Box 371916, United Arab Emirates.
- 5Medical Standards and Patient Care, Department of Health, Abu Dhabi P.O. Box 5674, United Arab Emirates.
- 6Syrenia Solutions, Dubai P.O. Box 123016, United Arab Emirates.
- 7Pharmacy Department, Sheikh Khalifa Medical City, Abu Dhabi P.O. Box 51900, United Arab Emirates.
- 8Payers Division, Department of Health, Abu Dhabi P.O. Box 5674, United Arab Emirates.
Abstract
Hemophilia A management in the United Arab Emirates (UAE) is still largely driven by treatment acquisition costs. This may limit access to innovative therapies such as emicizumab despite their broader clinical value. This paper aimed to identify barriers to value-based reimbursement and develop policy recommendations to strengthen health technology assessment (HTA) for hemophilia A in the UAE. An evidence-informed multi-stakeholder roundtable was held during the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) UAE Chapter 2026 Conference. The discussion was informed by published evidence, regional clinical guidance, and expert perspectives. The roundtable discussion was transcribed and summarized using descriptive qualitative analysis, and the manuscript synthesizes the main policy themes identified by the participants. Four priority areas emerged: adopting value-based assessment beyond acquisition cost, strengthening the use of evidence in reimbursement decisions, establishing national hemophilia registries with standardized data collection, and improving timely access to innovative therapies for high-risk patients. Overall, participants agreed that stronger HTA processes and better evidence generation are needed to support reimbursement decisions. Implementing these recommendations could improve access to innovative therapies and support more consistent, patient-centered, and sustainable hemophilia care in the UAE.
Related
- Facilitators and barriers influencing the implementation of type 2 diabetes remission programmes: a qualitative meta-synthesis from a multi-stakeholder perspective
- Perceived value and stakeholder experience of a dedicated allied health professions informatics role in a specialist cancer centre: a mixed-methods service evaluation survey
- Clinical laboratory diagnostic stewardship as boundary infrastructure: a multi-stakeholder qualitative study of digital public health governance in two Chinese regional referral hospitals
- Pet-inclusive housing as a social determinant of health: a multi-stakeholder qualitative study of rental policy and health equity
- From Evidence to Intervention: A Systematic, Multi-Stakeholder Approach to Developing and Prioritizing Diagnostic Excellence Interventions Across a 14-Site Hospital Medicine Collaborative
BibTeX
@article{dallal2026toward,
title = {{Toward Value-Based Reimbursement for Hemophilia A in the UAE: A Multi-Stakeholder Perspective.}},
author = {Sara Al Dallal and Hatem Abuieda and Nasser AlZain and Qassim Farouq and Shandhosh Raman and Sherif Mahmoud and Waiel Al Naeem and Ahmed Osman},
journal = {Journal of market access \& health policy},
year = {2026},
month = sep,
doi = {10.3390/jmahp14040058},
url = {https://europepmc.org/article/MED/42924715},
note = {CC BY},
}
RIS
TY - JOUR
TI - Toward Value-Based Reimbursement for Hemophilia A in the UAE: A Multi-Stakeholder Perspective.
AU - Sara Al Dallal
AU - Hatem Abuieda
AU - Nasser AlZain
AU - Qassim Farouq
AU - Shandhosh Raman
AU - Sherif Mahmoud
AU - Waiel Al Naeem
AU - Ahmed Osman
PY - 2026
DA - 2026/09/29
JO - Journal of market access & health policy
DO - 10.3390/jmahp14040058
UR - https://europepmc.org/article/MED/42924715
AB - Hemophilia A management in the United Arab Emirates (UAE) is still largely driven by treatment acquisition costs. This may limit access to innovative therapies such as emicizumab despite their broader clinical value. This paper aimed to identify barriers to value-based reimbursement and develop policy recommendations to strengthen health technology assessment (HTA) for hemophilia A in the UAE. An evidence-informed multi-stakeholder roundtable was held during the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) UAE Chapter 2026 Conference. The discussion was informed by published evidence, regional clinical guidance, and expert perspectives. The roundtable discussion was transcribed and summarized using descriptive qualitative analysis, and the manuscript synthesizes the main policy themes identified by the participants. Four priority areas emerged: adopting value-based assessment beyond acquisition cost, strengthening the use of evidence in reimbursement decisions, establishing national hemophilia registries with standardized data collection, and improving timely access to innovative therapies for high-risk patients. Overall, participants agreed that stronger HTA processes and better evidence generation are needed to support reimbursement decisions. Implementing these recommendations could improve access to innovative therapies and support more consistent, patient-centered, and sustainable hemophilia care in the UAE.
SN - 2001-6689
ER -